ABOUT TOPAZ

Nicholas U. Spring, BSc (Hons), DipM., Chartered Marketer

President and Chief Executive Officer

Mr. Nicholas U. Spring co- founded Topaz Pharmaceuticals, Inc. in March 2005 with Don Beeman and served variously as its Chairman, President and Chief Executive Officer until April 2010. During those five years he led the company through three rounds of private financing as well as pre-clinical development, IND, Phase I, II, IIb and the initiation of Phase III FDA trials. The company was recognized by the Eastern Technology Council Enterprise Awards as a "Company to Watch" in 2007 and was runner up as “Emerging Life Sciences Company of the Year” in 2009. He currently sits on the company's Board of Directors.

Prior to starting his own business, Mr. Spring was a senior executive at Merck & Co, where he led several divisions for global sales and marketing (including both human and animal health). While working in the Europe, USA and other global geographies, Mr. Spring's experience with ivermectin began to grow. He launched and managed many ivermectin-based formulations including Heartgard^®, Ivomec^®, Eqvalan^®, and Zimectrin^®. His interest in and experience with ivermectin inspired him to investigate using ivermectin in topical form for treating head lice – the concept on which Topaz is based.

Mr. Spring has nearly 30 years of pharmaceutical and consumer marketing experience. In addition to his role with Topaz Pharmaceuticals, Mr. Spring is an adjunct Associate Professor specializing in International Pharmaceutical Marketing at the University of Sciences in Philadelphia, PA. He holds a BSc Degree (with honors) in Applied Zoology from Leeds University in the UK and a post graduate Diploma in Marketing from the Chartered Institute of Marketing. He is also a Fellow of the Zoological Society of London.